An Improved <i>In Vitro</i> Pyrogen Test To Detect The Presence of Endotoxin Containing Bacteria Using Limulus <i>Amoebocyte Lysate</i> Assay From Pharmaceutical Raw Product
Most of the environmental organism possess endotoxin which presence indicates the organisms are much lethal and for the purposes bacteriological quality of pharmaceutical raw products is much important. In these current study, 2 raw materials out of 10 were found to containing pathogenic bacteria Escherichia coli and Pseudomonas species in the culture medium, that indicates the raw materials were contaminated with the deadly organism. These two raw materials checked for the presence of Endotoxin and both provided positive gel clot by Limulas amoebocyte lysate (LAL) assay. Quality maintenance and assurance is the essential need of Drug preparation in pharmaceutical sector. The result ensure that Pharmaceutical industry should need to follow GMP and HACCP to minimize the contamination for improving the biological safety of the product in a cost-effective manner.
Key Word: Limulas amoebocyte lysate (LAL) assay, Gram negative bacteria, endotoxin.
doi:10.3329/sjps.v1i1.1812 Â Â
S. J. Pharm. Sci. 1(1&2): 76-79
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.